Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke. / Thougaard, Estrid; Nielsen, Pernille Vinther; Forsberg, Amalie; Phuong, Victoria; Velasco, Aitana Martínez; Wlodarczyk, Agnieszka; Wajant, Harald; Lang, Isabell; Mikkelsen, Jens D.; Clausen, Bettina Hjelm; Brambilla, Roberta; Lambertsen, Kate Lykke.

In: Journal of Neuroimmunology, Vol. 385, 578246, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Thougaard, E, Nielsen, PV, Forsberg, A, Phuong, V, Velasco, AM, Wlodarczyk, A, Wajant, H, Lang, I, Mikkelsen, JD, Clausen, BH, Brambilla, R & Lambertsen, KL 2023, 'Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke', Journal of Neuroimmunology, vol. 385, 578246. https://doi.org/10.1016/j.jneuroim.2023.578246

APA

Thougaard, E., Nielsen, P. V., Forsberg, A., Phuong, V., Velasco, A. M., Wlodarczyk, A., Wajant, H., Lang, I., Mikkelsen, J. D., Clausen, B. H., Brambilla, R., & Lambertsen, K. L. (2023). Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke. Journal of Neuroimmunology, 385, [578246]. https://doi.org/10.1016/j.jneuroim.2023.578246

Vancouver

Thougaard E, Nielsen PV, Forsberg A, Phuong V, Velasco AM, Wlodarczyk A et al. Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke. Journal of Neuroimmunology. 2023;385. 578246. https://doi.org/10.1016/j.jneuroim.2023.578246

Author

Thougaard, Estrid ; Nielsen, Pernille Vinther ; Forsberg, Amalie ; Phuong, Victoria ; Velasco, Aitana Martínez ; Wlodarczyk, Agnieszka ; Wajant, Harald ; Lang, Isabell ; Mikkelsen, Jens D. ; Clausen, Bettina Hjelm ; Brambilla, Roberta ; Lambertsen, Kate Lykke. / Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke. In: Journal of Neuroimmunology. 2023 ; Vol. 385.

Bibtex

@article{24aabb44251e4e648ef62eb62c9f4aa3,
title = "Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke",
abstract = "Ischemic stroke often leaves survivors with permanent disabilities and therapies aimed at limiting detrimental inflammation and improving functional outcome are still needed. Tumor necrosis factor (TNF) levels increase rapidly after ischemic stroke, and while signaling through TNF receptor 1 (TNFR1) is primarily detrimental, TNFR2 signaling mainly has protective functions. We therefore investigated how systemic stimulation of TNFR2 with the TNFR2 agonist NewSTAR2 affects ischemic stroke in mice. We found that NewSTAR2 treatment induced changes in peripheral immune cell numbers and transiently affected microglial numbers and neuroinflammation. However, this was not sufficient to improve long-term functional outcome after stroke in mice.",
keywords = "Cytokines, Ischemic stroke, Microglia, Neuroinflammation, Peripheral immune cells, TNFR2 agonist",
author = "Estrid Thougaard and Nielsen, {Pernille Vinther} and Amalie Forsberg and Victoria Phuong and Velasco, {Aitana Mart{\'i}nez} and Agnieszka Wlodarczyk and Harald Wajant and Isabell Lang and Mikkelsen, {Jens D.} and Clausen, {Bettina Hjelm} and Roberta Brambilla and Lambertsen, {Kate Lykke}",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
doi = "10.1016/j.jneuroim.2023.578246",
language = "English",
volume = "385",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke

AU - Thougaard, Estrid

AU - Nielsen, Pernille Vinther

AU - Forsberg, Amalie

AU - Phuong, Victoria

AU - Velasco, Aitana Martínez

AU - Wlodarczyk, Agnieszka

AU - Wajant, Harald

AU - Lang, Isabell

AU - Mikkelsen, Jens D.

AU - Clausen, Bettina Hjelm

AU - Brambilla, Roberta

AU - Lambertsen, Kate Lykke

N1 - Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - Ischemic stroke often leaves survivors with permanent disabilities and therapies aimed at limiting detrimental inflammation and improving functional outcome are still needed. Tumor necrosis factor (TNF) levels increase rapidly after ischemic stroke, and while signaling through TNF receptor 1 (TNFR1) is primarily detrimental, TNFR2 signaling mainly has protective functions. We therefore investigated how systemic stimulation of TNFR2 with the TNFR2 agonist NewSTAR2 affects ischemic stroke in mice. We found that NewSTAR2 treatment induced changes in peripheral immune cell numbers and transiently affected microglial numbers and neuroinflammation. However, this was not sufficient to improve long-term functional outcome after stroke in mice.

AB - Ischemic stroke often leaves survivors with permanent disabilities and therapies aimed at limiting detrimental inflammation and improving functional outcome are still needed. Tumor necrosis factor (TNF) levels increase rapidly after ischemic stroke, and while signaling through TNF receptor 1 (TNFR1) is primarily detrimental, TNFR2 signaling mainly has protective functions. We therefore investigated how systemic stimulation of TNFR2 with the TNFR2 agonist NewSTAR2 affects ischemic stroke in mice. We found that NewSTAR2 treatment induced changes in peripheral immune cell numbers and transiently affected microglial numbers and neuroinflammation. However, this was not sufficient to improve long-term functional outcome after stroke in mice.

KW - Cytokines

KW - Ischemic stroke

KW - Microglia

KW - Neuroinflammation

KW - Peripheral immune cells

KW - TNFR2 agonist

U2 - 10.1016/j.jneuroim.2023.578246

DO - 10.1016/j.jneuroim.2023.578246

M3 - Journal article

C2 - 37988839

AN - SCOPUS:85177485223

VL - 385

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

M1 - 578246

ER -

ID: 374665936